title: Clinical inquiries. For those intolerant to ACE inhibitors and ARBs, what is the best therapy for reducing the risk of diabetic nephropathy?
authors.affiliation: Baylor University, Houston, TX, USA.
authors.forename: Santhi
authors.initials: S
authors.lastname: Penmetsa
authors.forename: Michael
authors.initials: M
authors.lastname: Simmons
authors.forename: Allen
authors.initials: A
authors.lastname: Daugird
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D003928:Diabetic Nephropathies / Q000517:prevention & control*; D004232:Diuretics / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D004232:Diuretics; D001262:Atenolol